🇺🇸 FDA
Patent

US 11654145

Combination therapy involving diaryl macrocyclic compounds

granted A61KA61K31/517A61K31/519

Quick answer

US patent 11654145 (Combination therapy involving diaryl macrocyclic compounds) held by TURNING POINT THERAPEUTICS, INC. expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TURNING POINT THERAPEUTICS, INC.
Grant date
Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/517, A61K31/519, A61K45/06, A61P